Sonja Chiappetta1,2, Christine Stier3, Rudolf A Weiner4. 1. Department of Obesity and Metabolic Surgery, Ospedale Evangelico Betania, Via Argine 604, 80147, Naples, Italy. sonja1002@gmx.de. 2. Department of Obesity and Metabolic Surgery, Sana Klinikum Offenbach, Offenbach am Main, Germany. sonja1002@gmx.de. 3. Adipositaszentrum, University Hospital of Würzburg, Würzburg, Germany. 4. Department of Obesity and Metabolic Surgery, Sana Klinikum Offenbach, Offenbach am Main, Germany.
Abstract
OBJECTIVE: To examine the relationship between Edmonton Obesity Staging System (EOSS) and perioperative complications as well as surgical procedure. BACKGROUND: The application of EOSS for the selection of patients with obesity is a more comprehensive measure of obesity-related diseases and a predictor of mortality than body mass index (BMI). METHODS: This was a nationwide cohort study using prospectively inserted data from the German register for obesity and metabolic surgery StuDoQ|MBE. All patients undergoing sleeve gastrectomy (SG), Roux-en Y gastric bypass (RYGB), and one-anastomosis gastric bypass (OAGB) between February 2015 and July 2017 as a primary treatment for severe obesity were included. Data included gender, age, BMI, ASA score, EOSS, early postoperative complications next to the Clavien-Dindo grading system, readmission, and 30-day mortality. RESULTS: A total of 9437 patients were included. The mean BMI was 49.5 kg/m2 ± 7.8 (range 35-103.5). The total postoperative complication rate was 5.3%, with the highest rate in EOSS 3 (7.8%) and 4 (6.8%). Thirty-day mortality was 0.2% with the highest mortality after SG in EOSS 3 (1.16%) and EOSS 4 (0.92%) (p = 0.0068). Crosstabs showed a prevalence of Clavien-Dindo III and IV complications of 3.4% (SG), 3.6% (RYGB), and 1.6% (OAGB) in EOSS 2 (p = 0.0032) and 3.5% (SG), 5.1% (RYGB), and 5.6% (OAGB) in EOSS 3. CONCLUSION: The highest postoperative complications and mortality occurred in patients with EOSS ≥ 3. SG and OAGB could be the procedure of choice to reduce perioperative morbidity; nevertheless, it has to be in mind that in EOSS ≥ 3, SG has the highest mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03556059.
OBJECTIVE: To examine the relationship between Edmonton Obesity Staging System (EOSS) and perioperative complications as well as surgical procedure. BACKGROUND: The application of EOSS for the selection of patients with obesity is a more comprehensive measure of obesity-related diseases and a predictor of mortality than body mass index (BMI). METHODS: This was a nationwide cohort study using prospectively inserted data from the German register for obesity and metabolic surgery StuDoQ|MBE. All patients undergoing sleeve gastrectomy (SG), Roux-en Y gastric bypass (RYGB), and one-anastomosis gastric bypass (OAGB) between February 2015 and July 2017 as a primary treatment for severe obesity were included. Data included gender, age, BMI, ASA score, EOSS, early postoperative complications next to the Clavien-Dindo grading system, readmission, and 30-day mortality. RESULTS: A total of 9437 patients were included. The mean BMI was 49.5 kg/m2 ± 7.8 (range 35-103.5). The total postoperative complication rate was 5.3%, with the highest rate in EOSS 3 (7.8%) and 4 (6.8%). Thirty-day mortality was 0.2% with the highest mortality after SG in EOSS 3 (1.16%) and EOSS 4 (0.92%) (p = 0.0068). Crosstabs showed a prevalence of Clavien-Dindo III and IV complications of 3.4% (SG), 3.6% (RYGB), and 1.6% (OAGB) in EOSS 2 (p = 0.0032) and 3.5% (SG), 5.1% (RYGB), and 5.6% (OAGB) in EOSS 3. CONCLUSION: The highest postoperative complications and mortality occurred in patients with EOSS ≥ 3. SG and OAGB could be the procedure of choice to reduce perioperative morbidity; nevertheless, it has to be in mind that in EOSS ≥ 3, SG has the highest mortality. TRIAL REGISTRATION: ClinicalTrials.gov Identifier NCT03556059.
Authors: Ninh T Nguyen; Mahbod Paya; C Melinda Stevens; Shahrzad Mavandadi; Kambiz Zainabadi; Samuel E Wilson Journal: Ann Surg Date: 2004-10 Impact factor: 12.969
Authors: Ali Aminian; Stacy A Brethauer; Amin Andalib; Amy S Nowacki; Amanda Jimenez; Ricard Corcelles; Zubaidah Nor Hanipah; Suriya Punchai; Deepak L Bhatt; Sangeeta R Kashyap; Bartolome Burguera; Antonio M Lacy; Josep Vidal; Philip R Schauer Journal: Ann Surg Date: 2017-10 Impact factor: 12.969
Authors: Daniel M Felsenreich; Lukas M Ladinig; Philipp Beckerhinn; Christoph Sperker; Katrin Schwameis; Michael Krebs; Julia Jedamzik; Magdalena Eilenberg; Christoph Bichler; Gerhard Prager; Felix B Langer Journal: Obes Surg Date: 2018-11 Impact factor: 4.129
Authors: Ralph Peterli; Bettina Karin Wölnerhanssen; Thomas Peters; Diana Vetter; Dino Kröll; Yves Borbély; Bernd Schultes; Christoph Beglinger; Jürgen Drewe; Marc Schiesser; Philipp Nett; Marco Bueter Journal: JAMA Date: 2018-01-16 Impact factor: 56.272
Authors: Yingjun Quan; Ao Huang; Min Ye; Ming Xu; Biao Zhuang; Peng Zhang; Bo Yu; Zhijun Min Journal: Gastroenterol Res Pract Date: 2015-06-17 Impact factor: 2.260
Authors: Raymond Kodsi; Ritesh Chimoriya; David Medveczky; Kathy Grudzinskas; Evan Atlantis; Abd A Tahrani; Nic Kormas; Milan K Piya Journal: Nutrients Date: 2022-02-24 Impact factor: 5.717
Authors: Rukia Swaleh; Taylor McGuckin; Tyler W Myroniuk; Donna Manca; Karen Lee; Arya M Sharma; Denise Campbell-Scherer; Roseanne O Yeung Journal: CMAJ Open Date: 2021-12-07